Physician profile
Anna Mathew
NPI 1750479499
$1,490.40
in general payments reported to CMS, 2019-2025
27 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $427.00 | 2019 | |
| Stryker Corporation | $142.86 | 2025 | Mako |
| Janssen Biotech, INC. | $91.70 | 2019 | |
| Genentech USA, INC. | $74.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.63 | 2019 | |
| Merck Sharp & Dohme LLC | $63.18 | 2019 | |
| Pfizer INC. | $60.15 | 2019 | |
| Amgen INC. | $55.55 | 2019 | |
| Eisai INC. | $51.10 | 2019 | |
| Genzyme Corporation | $49.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $40.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.85 | 2019 | |
| Abbvie INC. | $37.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.96 | 2019 | |
| Gilead Sciences, INC. | $32.40 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.62 | 2019 | |
| Lilly USA, LLC | $23.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.37 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.36 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.28 | 2019 | |
| Seagen INC. | $13.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.64 | 2019 | |
| Emd Serono, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.